Madrigal Pharmaceuticals Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Madrigal Pharmaceuticals Is Advancing Its NASH Pipeline in 2018

    Madrigal Pharmaceuticals (MDGL) is currently trading at price-to-book and price-to-cash-flow ratios of 5.6x and 5.81x, respectively.

    By Margaret Patrick
  • uploads///Part_Graph
    Company & Industry Overviews

    Madrigal Pharmaceuticals Stock in the First Half of October

    Madrigal Pharmaceuticals’ (MDGL) stock price has dropped by 10.87% from $212.26 on October 1 to $189.18 on October 15.

    By Margaret Patrick
  • uploads///medications _
    Company & Industry Overviews

    A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

    In this series, we’ll analyze three pharmaceutical companies with focused nonalcoholic steatohepatitis pipelines.

    By Kenneth Smith
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.

    By Daniel Collins
  • uploads///ecg _
    Company & Industry Overviews

    Galmed Stock Rose Over 26% on ‘Overweight’ Rating

    Today, Galmed Pharmaceuticals (GLMD) soared as Cantor Fitzgerald initiated coverage on the stock with an “overweight” rating and a target price of $59.

    By Sarah Collins
  • uploads///cells __
    Company & Industry Overviews

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.

    By Daniel Collins
  • uploads///RECOMMENDATIONS
    Company & Industry Overviews

    Analysts Are Bullish on Viking Therapeutics Stock

    On June 1, Viking Therapeutic had a consensus 12-month target price of $10.63, which implies a 12-month investment return potential of ~4.7%.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Viking Therapeutics Stock Rose 101% on May 31

    On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.